Manik Kuchroo

Manik Kuchroo

Senior Associate atPolaris PartnersBoston

Manik Kuchroo is a senior associate at Polaris Partners, focusing on early-stage biotech. He has clinical development and business development experience at Biohaven Pharmaceuticals, Potenza Therapeutics, and Merck & Co.

What Manik can write

Writes checks of$500K to $10M
Comes in atSeed, Series AMostly follows a lead
Best routeA warm introAsk a founder in their portfolio.

Polaris Partners writes $500K to $10M checks, larger than 71% of firms in the atlas.

Bars: how many firms report each check band. Highlighted: Polaris Partners.

Career

  1. Merck & Co. · Computational Genomics research group
  2. Potenza Therapeutics · business development
  3. Biohaven Pharmaceuticals · clinical development
  4. Polaris Partners · Senior Associate
    Now

Focus

early-stage biotechimmunologyoncologyneuroscience

Education

Yale School of Medicine, MD and PhDHarvard College

Also at Polaris Partners

Partners like Manik

At firms with a similar stage, sector and check size.

Alert me when Polaris Partners is active

One email when Manik's firm raises a fund, adds a partner or shows new activity.

Founders and investors at a Mode VC gathering

Send Mode VC your deck

Raising a pre-seed or seed round? We write $1M to $5M first checks and help founders with distribution. A partner reads every deck.

Send your deck

Questions

Who is Manik Kuchroo?

Manik Kuchroo is a senior associate at Polaris Partners, focusing on early-stage biotech. He has clinical development and business development experience at Biohaven Pharmaceuticals, Potenza Therapeutics, and Merck & Co.

How much does Manik Kuchroo invest?

Manik Kuchroo invests through Polaris Partners, which writes checks of $500K to $10M at seed, series a.

How do I pitch Manik Kuchroo?

A warm intro from a founder Polaris Partners backed works best.

What did Manik Kuchroo do before Polaris Partners?

Computational Genomics research group at Merck & Co.; business development at Potenza Therapeutics; clinical development at Biohaven Pharmaceuticals.

Last updated 2026-10-15. Is this you? Ask for a correction.